RU2021117812A - Противораковые вакцины, нацеленные на сурвивин, и их применения - Google Patents
Противораковые вакцины, нацеленные на сурвивин, и их применения Download PDFInfo
- Publication number
- RU2021117812A RU2021117812A RU2021117812A RU2021117812A RU2021117812A RU 2021117812 A RU2021117812 A RU 2021117812A RU 2021117812 A RU2021117812 A RU 2021117812A RU 2021117812 A RU2021117812 A RU 2021117812A RU 2021117812 A RU2021117812 A RU 2021117812A
- Authority
- RU
- Russia
- Prior art keywords
- isoform
- survivin
- antigen
- nucleic acid
- vaccine
- Prior art date
Links
- 229940022399 cancer vaccine Drugs 0.000 title 1
- 230000008685 targeting Effects 0.000 title 1
- 239000000427 antigen Substances 0.000 claims 13
- 102000036639 antigens Human genes 0.000 claims 13
- 108091007433 antigens Proteins 0.000 claims 13
- 102100021663 Baculoviral IAP repeat-containing protein 5 Human genes 0.000 claims 11
- 108010002687 Survivin Proteins 0.000 claims 11
- 102000001708 Protein Isoforms Human genes 0.000 claims 10
- 108010029485 Protein Isoforms Proteins 0.000 claims 10
- 150000007523 nucleic acids Chemical class 0.000 claims 8
- 238000000034 method Methods 0.000 claims 6
- 102000039446 nucleic acids Human genes 0.000 claims 6
- 108020004707 nucleic acids Proteins 0.000 claims 6
- 229960005486 vaccine Drugs 0.000 claims 6
- 101000896234 Homo sapiens Baculoviral IAP repeat-containing protein 5 Proteins 0.000 claims 4
- 102000047803 human BIRC5 Human genes 0.000 claims 4
- 230000035772 mutation Effects 0.000 claims 4
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 3
- 102220533217 Baculoviral IAP repeat-containing protein 5_C84A_mutation Human genes 0.000 claims 2
- 102220533139 Baculoviral IAP repeat-containing protein 5_T34A_mutation Human genes 0.000 claims 2
- 102220533150 Baculoviral IAP repeat-containing protein 5_T48E_mutation Human genes 0.000 claims 2
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 2
- 239000002671 adjuvant Substances 0.000 claims 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 2
- 150000001413 amino acids Chemical class 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 238000004520 electroporation Methods 0.000 claims 2
- 239000013604 expression vector Substances 0.000 claims 2
- 230000002163 immunogen Effects 0.000 claims 2
- 102000004169 proteins and genes Human genes 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 239000013598 vector Substances 0.000 claims 2
- 102000001327 Chemokine CCL5 Human genes 0.000 claims 1
- 108010055166 Chemokine CCL5 Proteins 0.000 claims 1
- 230000024932 T cell mediated immunity Effects 0.000 claims 1
- 230000028996 humoral immune response Effects 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 239000013612 plasmid Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001148—Regulators of development
- A61K39/00115—Apoptosis related proteins, e.g. survivin or livin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/52—Genes encoding for enzymes or proenzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55522—Cytokines; Lymphokines; Interferons
- A61K2039/55527—Interleukins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
- A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/80—Vaccine for a specifically defined cancer
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biochemistry (AREA)
- Veterinary Medicine (AREA)
- Biophysics (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Plant Pathology (AREA)
- Epidemiology (AREA)
- Physics & Mathematics (AREA)
- Mycology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Virology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Claims (22)
1. Молекула нуклеиновой кислоты, которая кодирует синтетический антиген сурвивина, где указанная молекула нуклеиновой кислоты содержит последовательность нуклеиновой кислоты, кодирующую белок изоформы 1 синтетического консенсусного антигена сурвивина, имеющий:
i. между 95% и 98% гомологии аминокислотной последовательности с изоформой 1 нативного человеческого антигена сурвивина, и
ii. по меньшей мере три аминокислотные мутации, соответствующие мутациям T34A, T48A и C84A в изоформе 1 нативного человеческого антигена сурвивина.
2. Молекула нуклеиновой кислоты по п. 1, где указанная молекула нуклеиновой кислоты дополнительно содержит последовательность нуклеиновой кислоты, кодирующую укороченную изоформу 3 синтетического консенсусного антигена сурвивина, имеющую между 95% и 98% гомологии последовательности с изоформой 3 нативного человеческого антигена сурвивина.
3. Синтетический антиген сурвивина, содержащий белок изоформы 1 синтетического консенсусного антигена сурвивина, имеющий:
i. между 95% и 98% гомологии аминокислотной последовательности с изоформой 1 нативного человеческого антигена срвивина, и
ii. по меньшей мере три аминокислотные мутации, соответствующие мутациям T34A, T48A и C84A в изоформе 1 нативного человеческого антигена сурвивина.
4. Синтетический антиген сурвивина по п. 3, где указанный антиген дополнительно содержит укороченную изоформу 3 синтетического консенсусного антигена сурвивина, имеющую между 95% и 98% гомологии последовательности с изоформой 3 нативного человеческого антигена сурвивина.
5. Экспрессионный вектор, содержащий молекулу нуклеиновой кислоты по п. 1 или 2.
6. Экспрессионный вектор по п. 5, содержащий плазмиду.
7. Иммуногенная композиция, содержащая эффективное количество молекулы нуклеиновой кислоты по п. 1 или 2 и фармацевтически приемлемый носитель.
8. Иммуногенная композиция, содержащая эффективное количество вектора по п. 5 или 6 и фармацевтически приемлемый носитель.
9. Вакцина для лечения или предотвращения сурвивин-экспрессирующего рака, содержащая эффективное количество вектора по п. 5 или 6.
10. Вакцина по п. 9, дополнительно содержащая фармацевтически приемлемый наполнитель.
11. Вакцина по п. 9 или 10, дополнительно содержащая адъювант.
12. Вакцина по п. 11, где адъювант представляет собой IL-12, IL-15, IL-28 или RANTES.
13. Способ лечения субъекта с сурвивин-экспрессирующей раковой клеткой, включающий введение терапевтически эффективного количества вакцины любому из пп. 9-12.
14. Способ по п. 13, где введение включает электропорацию.
15. Способ по п. 13, где введение происходит в одном или в более местах у субъекта.
16. Способ вакцинации субъекта против сурвивин-экспрессирующей раковой клетки, включающий введение количества вакцины по любому из пп. 9-12, эффективного для индукции гуморального или клеточного иммунного ответа.
17. Способ по п. 16, где введение включает электропорацию.
18. Способ по п. 16, где введение происходит в одном или в более местах у субъекта.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762598267P | 2017-12-13 | 2017-12-13 | |
| US62/598,267 | 2017-12-13 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2020122872A Division RU2751253C1 (ru) | 2017-12-13 | 2018-12-13 | Противораковые вакцины, нацеленные на сурвивин, и их применения |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| RU2021117812A true RU2021117812A (ru) | 2021-07-26 |
| RU2021117812A3 RU2021117812A3 (ru) | 2021-11-08 |
| RU2776949C2 RU2776949C2 (ru) | 2022-07-29 |
Family
ID=
Also Published As
| Publication number | Publication date |
|---|---|
| RU2021117812A3 (ru) | 2021-11-08 |
| US20190175707A1 (en) | 2019-06-13 |
| KR20200096957A (ko) | 2020-08-14 |
| CA3083534A1 (en) | 2019-06-20 |
| KR20240038139A (ko) | 2024-03-22 |
| MX2020006285A (es) | 2020-09-17 |
| JP2021506265A (ja) | 2021-02-22 |
| EP3723793A2 (en) | 2020-10-21 |
| AU2018383664A1 (en) | 2020-07-16 |
| JP7385569B2 (ja) | 2023-11-22 |
| EP3723793A4 (en) | 2022-01-19 |
| BR112020011820A2 (pt) | 2020-11-17 |
| WO2019118766A2 (en) | 2019-06-20 |
| KR102648079B1 (ko) | 2024-03-18 |
| JP2023155245A (ja) | 2023-10-20 |
| CN111479583A (zh) | 2020-07-31 |
| RU2751253C1 (ru) | 2021-07-12 |
| WO2019118766A3 (en) | 2019-09-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Gong et al. | The current status, challenges, and future developments of new tuberculosis vaccines | |
| Ingolotti et al. | DNA vaccines for targeting bacterial infections | |
| RU2014144133A (ru) | Простатоассоциированные антигены и иммунотерапевтические схемы на основе вакцин | |
| RU2016146801A (ru) | Вакцинная композиция против инфекции, вызванной streptococcus suis | |
| ES2925950T3 (es) | Composiciones para la tuberculosis y procedimientos de uso de las mismas | |
| US10799572B2 (en) | Consensus antigen constructs and vaccines made therefrom, and methods of using the same to treat malaria | |
| BR112021026439A2 (pt) | Vacina para febre suína africana | |
| BRPI0905725B1 (pt) | vacina e embalagem farmacêutica | |
| Zhang et al. | Evaluation of the immune response induced by multiantigenic DNA vaccine encoding SAG1 and ROP2 of Toxoplasma gondii and the adjuvant properties of murine interleukin-12 plasmid in BALB/c mice | |
| EP2341926B1 (en) | Method for purifying heat shock protein complexes | |
| Umthong et al. | Immunogenicity of a DNA and recombinant protein vaccine combining LipL32 and Loa22 for leptospirosis using chitosan as a delivery system | |
| Lu et al. | Alpha-galactosylceramide enhances protective immunity induced by DNA vaccine of the SAG5D gene of Toxoplasma gondii | |
| ES2898701T3 (es) | Proteína VP4 de rotavirus truncada y aplicación de la misma | |
| EP3715359A1 (en) | Cd4 helper t cell epitope fusion peptide and vaccine therewith | |
| JP2014139185A5 (ru) | ||
| RU2014140731A (ru) | Варианты гемагглютинина и нейраминидазы гриппа | |
| EP2442825B1 (en) | Method for the purification of protein complexes | |
| RU2021117812A (ru) | Противораковые вакцины, нацеленные на сурвивин, и их применения | |
| WO2018102774A8 (en) | Pneumococcal vaccine combining selected alpha helical domains and proline rich domains of pneumococcal surface protein a | |
| Silveira et al. | Saccharomyces boulardii improves humoral immune response to DNA vaccines against leptospirosis | |
| RU2018123307A (ru) | Вакцинация с использованием альфа3 домена mica/b для лечения рака | |
| PH12020500194A1 (en) | Malaria vaccine | |
| CN102266551B (zh) | 可用于治疗人或动物免疫相关性疾病的白介素-4治疗性疫苗 | |
| FI3737397T3 (fi) | Prameen kohdistetut syöpärokotteet ja niiden käytöt | |
| Bagley et al. | The catalytic A1 domains of cholera toxin and heat-labile enterotoxin are potent DNA adjuvants that evoke mixed Th1/Th17 cellular immune responses |